#Micro cap stocks to watch trial#
On June 15, Immunic announced that the first patients in its Phase 2 CALVID-1 clinical trial of IMU-838 in COVID-19 had been dosed.
Other promising drugs that Immunic is developing include IMU-935, a treatment for autoimmune diseases and MU-856, a treatment for gastrointestinal disorders.
IMU-838 is currently being tested in four Phase 2 studies for multiple indications including COVID-19. The company’s lead prospect is IMU-838, an orally-dosed DHODH (an enzyme in humans that is encoded by the DHODH gene on chromosome 16) inhibitor. The first stock on our list is New York-based Immunic, a pharmaceutical company developing drugs to treat chronic autoimmune, inflammatory and viral diseases, with its market cap landing at only $182.9 million. Not to mention each boasts excellent upside potential. To this end, we used TipRanks’ database to pinpoint three micro-cap stocks that have earned a “Strong Buy” consensus rating from the analyst community. The experts possess extensive knowledge about the stocks they cover, and offer insights on compelling names that don’t always get the same attention as other heavyweights. On top of this, there are numerous and sometimes conflicting investing strategies to consider.īearing this in mind, Wall Street analysts can provide some inspiration. How are investors supposed to determine which stocks are poised to take off? Will the current winners continue climbing, or will new high-flyers emerge? Finding the next big one is challenging to say the least. Despite the adverse effects from COVID-19, the index is up 25% over the past year, and recently hit a new all-time high.
The index is home to surging technology, internet, and biotech stocks. If you are looking to hit a home run in the stock market, the NASDAQ Composite is a good place to start.
0 kommentar(er)
